文献速递肾癌与肾肿瘤

CheckMate 214:纳武利尤单抗联合伊匹木单抗疗效与IMDC风险因素数量的关系

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
PubMed 文献 · Eur Urol · 2019-11-13

CheckMate 214是一项随机、开放标签的3期试验,比较纳武利尤单抗联合伊匹木单抗与舒尼替尼在未经治疗的IMDC中危或低危晚期肾细胞癌患者中的疗效。本事后分析(n=1051)按IMDC风险因素数量评估疗效,发现联合治疗组客观缓解率在各风险因素数量(0-6个)间一致,而舒尼替尼组随风险因素增加而下降;联合治疗在1、2、3及4-6个风险因素亚组中均显示优于舒尼替尼的ORR、OS和PFS获益。

要点

  • 纳武利尤单抗联合伊匹木单抗一线治疗IMDC中危/低危晚期肾细胞癌,疗效不受IMDC风险因素数量影响。
  • 联合治疗ORR为40-44%,舒尼替尼为16-38%;OS HR 0.50-0.72,PFS HR 0.44-0.86。
  • 交互作用检验P<0.05,支持在各风险因素数量亚组中联合治疗均优于舒尼替尼。

核心结论

  • 在IMDC中危和低危晚期肾细胞癌患者中,无论治疗前风险因素数量多少,一线纳武利尤单抗联合伊匹木单抗均较舒尼替尼显示一致疗效获益。

研究设计与样本

  • 随机、开放标签、3期CheckMate 214试验的事后分析,纳入1051例未经治疗的IMDC中危或低危晚期肾细胞癌患者。
  • 患者接受纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周共4次,随后纳武利尤单抗3 mg/kg每2周;或舒尼替尼50 mg每日一次,服4周停2周。

主要发现

  • 纳武利尤单抗联合伊匹木单抗的ORR在0至6个IMDC风险因素间保持一致,而舒尼替尼的ORR随风险因素数量增加而下降。
  • 在1、2、3及4-6个风险因素亚组中,联合治疗较舒尼替尼的ORR为40-44% vs 16-38%,OS HR 0.50-0.72,PFS HR 0.44-0.86。
  • 治疗与风险因素数量交互作用检验P<0.05。

关键数值与推荐

  • 疗效评估包括研究者评估的ORR、OS和PFS(依据RECIST v1.1)。
  • 亚组分析基于IMDC风险因素数量(1、2、3、4-6个)。

临床怎么用

  • 对于IMDC中危或低危晚期肾细胞癌患者,一线可考虑纳武利尤单抗联合伊匹木单抗,无需因风险因素数量较少而排除。

局限性

  • 本分析为事后分析,非预设主要分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the randomized, open-label, phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk) had superior efficacy over sunitinib (50 mg once daily, 4 wk on, 2 wk off) in patients with untreated International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- or poor-risk advanced renal cell carcinoma; the benefits were sustained through extended follow-up. To better characterize the association between outcomes and IMDC risk in CheckMate 214, we completed a post hoc analysis (n = 1051) of efficacy by the number of IMDC risk factors. The investigator-assessed objective response rate (ORR), overall survival (OS), and investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors v1.1 were evaluated. ORR with nivolumab plus ipilimumab was consistent across zero to six IMDC risk factors, whereas with sunitinib it decreased with increasing number of risk factors. Benefits of nivolumab plus ipilimumab over sunitinib in terms of ORR (40-44% vs 16-38%), OS (hazard ratio [HR] 0.50-0.72), and PFS (HR 0.44-0.86) were consistently observed in subgroups with one, two, three, or four to six IMDC risk factors (p < 0.05 for treatment × no. of risk factors interaction). These results demonstrate the benefit of first-line nivolumab plus ipilimumab over sunitinib across all intermediate-risk and poor-risk groups, regardless of the number of IMDC risk factors. PATIENT SUMMARY: This report from the CheckMate 214 study describes a consistent efficacy benefit with first-line nivolumab plus ipilimumab over first-line sunitinib in all groups of patients with intermediate-risk or poor-risk advanced renal cell carcinoma, regardless of the number of risk factors they had before starting treatment. We conclude that there is a benefit of first-line treatment with nivolumab plus ipilimumab for all intermediate-risk patients, including those with one or two risk factors, and for all poor-risk patients, independent of the number of risk factors.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Escudier B, Motzer RJ, Tannir NM, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2019. PMID: 31732098. doi:10.1016/j.eururo.2019.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。